Advertisement

Search Results

Advertisement



Your search for Matthew Stenger,Matthew Stenger matches 7330 pages

Showing 1 - 50


pancreatic cancer
pain management

Pancreatic Cancer: Celiac Plexus Radiosurgery for Retroperitoneal Pain Syndrome

In a phase II study reported in The Lancet Oncology, Lawrence et al found that celiac plexus radiosurgery showed promise in the alleviation of retroperitoneal pain syndrome in patients with pancreatic cancer or other tumors involving the celiac axis. Study Details Between January 2018 and December...

hepatobiliary cancer
immunotherapy

Immunotherapy in Unresectable HCC With Child-Pugh Class B Dysfunction

In a retrospective study reported in JAMA Oncology, Fulgenzi et al found evidence that immune checkpoint inhibitor (ICI)-based treatment may improve survival vs best supportive care as first-line therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh class B (CP-B) liver...

breast cancer

Tailored Dose-Dense Adjuvant Chemotherapy in High-Risk Early Breast Cancer

As reported in the Journal of Clinical Oncology by Matikas et al, the prespecified end-of-study analysis of the European phase III PANTHER trial showed significant improvements in outcomes with tailored dose-dense vs standard adjuvant chemotherapy in patients with high-risk early breast cancer. As...

colorectal cancer
immunotherapy

pMMR/MSS Locally Advanced Rectal Cancer: Immunotherapy-Based Total Neoadjuvant Therapy

In a Chinese phase II trial (TORCH) reported in the Journal of Clinical Oncology, Xia et al found that integration of the PD-1 inhibitor toripalimab into total neoadjuvant therapy was associated with good outcomes in patients with mismatch repair–proficient or microsatellite-stable (pMMR/MSS)...

breast cancer
genomics/genetics

Early Breast Cancer: Genetic Testing and Communication of Results With Family After Diagnosis

In a U.S. study reported in the Journal of Clinical Oncology, Steven J. Katz, MD, MPH, and colleagues found that many women with early breast cancer and indications for genetic testing do not undergo said testing. Study Details    The study involved data from 1,412 women aged 20 to 79 years...

lymphoma

Response-Adapted Radiation Therapy for Orbital Indolent B-Cell Lymphoma

In a single-institution phase II trial reported in JAMA Oncology, Pinnix et al found that response-adapted radiation therapy featuring ultra–low-dose radiation therapy was a successful strategy in patients with indolent B-cell lymphoma of the ocular adnexa. As stated by the investigators:...

solid tumors

EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors

In a Chinese phase I trial reported in The Lancet Oncology, Ma et al found that BL-B01D1—a first-in-class EGFR-HER3 bispecific antibody-drug conjugate—was active in previously treated patients with locally advanced or metastatic solid tumors. Study Details In the multicenter trial, 195 patients...

lymphoma
immunotherapy

LBCL: CD22-Directed CAR T-Cell Therapy After Disease Progression on CD19-Directed CAR T-Cell Therapy

In a single-center phase I trial reported in The Lancet, Frank et al found that CD22-directed chimeric antigen receptor (CAR) T-cell therapy (CAR22) showed activity in patients with large B-cell lymphoma (LBCL) whose disease progressed on CD19-directed CAR T-cell therapy (CAR19). CD22 is a nearly...

gynecologic cancers

Recurrent Cervical Cancer: Tisotumab Vedotin in Second- or Third-Line Therapy

As reported in The New England Journal of Medicine by Ignace Vergote, MD, PhD, and colleagues, interim analysis of the phase III innovaTV 301 trial has shown improved overall survival and other efficacy outcomes with the antibody-drug conjugate tisotumab vedotin-tftv vs investigator’s choice of...

breast cancer
supportive care

Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: Effect of Denosumab on Bone Loss

In an Australian single-center trial reported in the Journal of Clinical Oncology, Ramchand et al found that denosumab prevented bone loss vs placebo in premenopausal women with estrogen receptor–positive breast cancer receiving estradiol suppression therapy. Study Details In the double-blind...

lymphoma

Advanced Classical Hodgkin Lymphoma: PET-Guided BrECADD vs eBEACOPP

As reported in The Lancet by Peter Borchmann, MD, and colleagues, the phase III HD21 trial showed that first-line positron-emission tomography (PET)-guided BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) exhibited greater efficacy and...

prostate cancer

Prostate Cancer Detection With AI vs Radiologist Readings of MRI

In a study reported in The Lancet Oncology (PI-CAI), Saha et al found that an artificial intelligence (AI) system’s readings of magnetic resonance imaging (MRI) outperformed study radiologist readings using Prostate Imaging—Reporting and Data System (PI-RADS) version 2.1 in detecting clinically...

breast cancer
genomics/genetics

Outcomes for BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Therapy

In a single-center study reported in JAMA Network Open, Kerollos Nashat Wanis, MD, PhD, and colleagues found that women with breast cancer and a pathogenic BRCA1/2 variant who underwent breast-conserving therapy had a 71% rate of 10-year bilateral mastectomy–free survival. Study Details The study...

breast cancer

Stage I HER2-Positive Breast Cancer: Long-Term Follow-up of Adjuvant T-DM1

In a 5-year update of the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Tarantino et al found that 1 year of adjuvant ado-trastuzumab emtansine (T-DM1) was associated with “outstanding” long-term outcomes in patients with stage I HER2-positive breast cancer. Study Details In...

hepatobiliary cancer

Adjuvant Therapeutic Regimens for Gallbladder Cancer

In an Indian phase II trial (GECCOR-GB) reported in JAMA Oncology, Ostwal et al found that both adjuvant gemcitabine/cisplatin (GC) and capecitabine and capecitabine given concurrently with chemoradiation therapy (CCRT) showed activity in patients with resected gallbladder cancer. Study Details In...

pancreatic cancer

Surveillance for Pancreatic Cancer in High-Risk Individuals

In a study reported in JAMA Oncology, Blackford et al found that surveillance of individuals at high risk for pancreatic ductal adenocarcinoma allowed for detection of earlier-stage pancreatic ductal adenocarcinoma—with improved survival—compared with matched pancreatic ductal adenocarcinoma...

pancreatic cancer
immunotherapy

Resected Pancreatic Cancer: Autologous Dendritic Cell Vaccination

In a Dutch single-center phase I/II study reported in the Journal of Clinical Oncology, van ‘t Land et al found that adjuvant autologous dendritic cell vaccination was associated with promising recurrence-free survival in patients who had undergone resection and standard-of-care treatments for...

prostate cancer
genomics/genetics

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

In a study reported in JAMA Network Open, Plym et al found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the disease. Study Details The cohort study used a combined analysis of...

breast cancer

Predictive Models for Disease Recurrence After Breast-Conserving Surgery for DCIS

In a Canadian study reported in the Journal of Clinical Oncology, Hahn et al evaluated the impact of certain predictive models for local and invasive local recurrence in patients undergoing breast-conserving surgery with or without adjuvant radiotherapy for pure ductal carcinoma in situ (DCIS)....

breast cancer

Capivasertib With Fulvestrant for Previously Treated Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

On November 16, 2023, capivasertib (Truqap) was approved for use with fulvestrant for patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, following disease progression on at least one endocrine-based...

breast cancer

Factors Impacting Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer

In a Danish study reported in the Journal of Clinical Oncology by Schmidt et al, it was found that living alone and being unemployed were associated with reduced adherence to adjuvant endocrine therapy among premenopausal women with breast cancer. Study Details The study involved data from a...

solid tumors

Relapsed or Refractory Neuroblastoma: Addition of Dasatinib/Rapamycin to Irinotecan/Temozolomide

In a German-Austrian phase II trial (RIST-rNB-2011) reported in The Lancet Oncology, Corbacioglu et al found that the combination of dasatinib plus rapamycin and irinotecan plus temozolomide (RIST) improved progression-free survival vs irinotecan/temozolomide alone in patients with high-risk...

bladder cancer
kidney cancer

Advanced/Metastatic Genitourinary Tumors: Cabozantinib/Nivolumab With or Without Ipilimumab

As reported in the Journal of Clinical Oncology by Andrea B. Apolo, MD, and colleagues, findings in expansion cohorts of a phase I study showed the activity of cabozantinib/nivolumab alone or with the addition of ipilimumab in patients with advanced/metastatic genitourinary (GU) tumors. Study...

breast cancer
supportive care
symptom management
genomics/genetics

Germline Risk of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Results from the ECOG-ACRIN EAZ171 trial—reported in the Journal of Clinical Oncology by Schneider et al—showed that germline predictors of taxane-induced peripheral neuropathy were not associated with an increased risk of taxane-induced peripheral neuropathy in Black women with early-stage breast...

issues in oncology

Tumor Surveillance in Pediatric Patients With Cancer Predisposition Syndromes

In a single-center study reported in JAMA Oncology, Blake et al found that surveillance among pediatric patients with cancer predisposition syndromes can result in the early detection of new tumors.  As stated by the investigators, “Pediatric oncology patients are increasingly recognized as having...

skin cancer

Advanced Melanoma: Efficacy of Monoclonal Antibody Doublet

In a phase I trial reported in the Journal of Clinical Oncology, Omid Hamid, MD, and colleagues found that the combination of the human lymphocyte activation gene-3 (LAG-3)-targeting monoclonal antibody fianlimab plus the PD-1–targeting monoclonal antibody cemiplimab-rwlc was active in patients...

gynecologic cancers

Endometrial Thickness in Triage for Endometrial Cancer Among Black Women

In a study reported in JAMA Oncology, Kemi Doll, MD, MSCR, and colleagues found that ultrasonography-measured endometrial thickness was not reliable in triage for diagnosing endometrial cancer among Black women. Study Details The retrospective U.S. multicenter study focused on data from 1,494 women ...

sarcoma

Previously Untreated Intermediate-Risk Rhabdomyosarcoma: Addition of Temsirolimus to Chemotherapy in Young Patients

As reported in The Lancet Oncology by Gupta et al, the phase III Children’s Oncology Group ARST1431 trial showed no event-free survival benefit with the addition of temsirolimus to chemotherapy in previously untreated children, adolescents, or young adults with intermediate-risk rhabdomyosarcoma....

lung cancer

Previously Untreated EGFR-Mutated Advanced NSCLC: Amivantamab/Lazertinib vs Osimertinib

As reported in The New England Journal of Medicine by Byoung Chul Cho, MD, PhD, and colleagues, the phase III MARIPOSA trial has shown improved progression-free survival with amivantamab-vmjw plus lazertinib vs osimertinib in previously untreated patients with EGFR-mutated advanced non–small cell...

multiple myeloma

Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody

As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma....

kidney cancer

Perioperative Nivolumab in Renal Cell Carcinoma

As reported in The Lancet Oncology by Allaf et al, a planned interim analysis of the phase III PROSPER ECOG-ACRIN EA8143 trial showed no recurrence-free survival benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma.  Study ...

breast cancer

Primary Breast Cancer: Pretreatment Exercise Level and Distant Recurrence–Free Interval

In a French study (CANTO) reported in the Journal of Clinical Oncology, Soldato et al found that increasing pretreatment exercise levels was associated with a longer distant recurrence–free interval up to a threshold exercise level in patients with primary breast cancer. The benefit of exercise...

multiple myeloma

Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Trial

As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, long-term follow-up of the phase III CASSIOPEIA trial has shown improved progression-free survival with daratumumab maintenance vs observation both among newly diagnosed patients with transplant-eligible multiple myeloma who ...

colorectal cancer

Adding COX-2 Inhibition to Chemotherapy in PIK3CA-Activated Stage III Colon Cancer

In an analysis from the CALGB/SWOG 80702 (Alliance) trial published by Nowak et al in the Journal of Clinical Oncology, researchers found that the addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy was associated with improved disease-free survival and...

head and neck cancer

Recurrent or Metastatic HNSCC: First-Line VEGFR2 Plus PD-1 Inhibition

In a single-center phase I/II trial reported in The Lancet Oncology, Douglas Adkins, MD, and colleagues found that the recommended phase II dose of ramucirumab combined with pembrolizumab was active in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell...

breast cancer

ER-Positive Advanced Breast Cancer: Oral SERD Plus Palbociclib in First-Line Setting

As reported in the Journal of Clinical Oncology by Javier Cortés, MD, PhD, and colleagues, the phase III AMEERA-5 trial of first-line treatment with the selective estrogen receptor degrader (SERD) amcenestrant plus palbociclib vs letrozole plus palbociclib in estrogen receptor (ER)-positive,...

gynecologic cancers

Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

On March 22, 2024, mirvetuximab soravtansine-gynx (Elahere) was granted regular approval for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment...

cns cancers

Tovorafenib in Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

On April 23, 2024, tovorafenib (Ojemda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for patients aged 6 months and older who have relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation.1 Tovorafenib is a...

Lu-177 Dotatate for Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

On April 23, 2024, lutetium Lu-177 dotatate (Lutathera) was approved for pediatric patients 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.1 Lu-177 dotatate is a radiolabeled...

breast cancer

Addition of Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy Improves Survival in Early Breast Cancer

As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of...

gastroesophageal cancer
immunotherapy

Pembrolizumab/Chemotherapy in First-Line Treatment of HER2-Negative Advanced Gastric or GEJ Adenocarcinoma

On November 16, 2023, pembrolizumab (Keytruda) was approved with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.1 Supporting Efficacy Data Approval ...

cns cancers

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.1 This represents the first...

lung cancer

Adjuvant Use of Alectinib in ALK-Positive NSCLC

On April 18, 2024, the ALK inhibitor alectinib was approved by the U.S. Food and Drug Administration (FDA) for adjuvant treatment after tumor resection in patients with ALK-positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test.1 Supporting Efficacy Data Approval was based ...

colorectal cancer

Metastatic Colorectal Cancer: Addition of Atezolizumab to First-Line FOLFOXIRI/Bevacizumab

As reported in the Journal of Clinical Oncology by Antoniotti et al, 4-year follow-up of the Italian phase II ATEZOTRIBE trial showed a numeric benefit in overall survival with the addition of atezolizumab to first-line FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and...

kidney cancer

Previously Untreated Advanced Clear Cell RCC: Bempegaldesleukin/Nivolumab vs TKI Therapy

As reported in the Journal of Clinical Oncology by Nizar M. Tannir, MD, FACP, and colleagues, the phase III PIVOT-09 trial has shown no objective response or overall survival benefit with bempegaldesleukin plus nivolumab vs tyrosine kinase inhibitor (TKI) treatment with sunitinib or cabozantinib in ...

solid tumors
hematologic malignancies
immunotherapy

Risk of Secondary Cancer After CAR T-Cell Therapy

In a single-center study reported in The New England Journal of Medicine, Hamilton et al found that second tumors had occurred in 25 of 724 patients during 15 months of follow-up after receipt of chimeric antigen receptor (CAR) T-cell therapy, including one fatal case of T-cell lymphoma. The study...

gastroesophageal cancer

Esophageal Cancer: Neoadjuvant Triplet or Doublet Chemotherapy, With or Without Radiotherapy

As reported in The Lancet by Ken Kato, MD, and colleagues, the Japanese phase III JCOG1109 NExT trial showed that neoadjuvant triplet chemotherapy was associated with superior overall survival vs doublet chemotherapy among previously untreated patients with locally advanced esophageal squamous cell ...

lung cancer

Lorlatinib vs Crizotinib in Previously Untreated Advanced ALK-Positive NSCLC

As reported in the Journal of Clinical Oncology by Benjamin J. Solomon, MBBS, PhD, and colleagues, analysis of 5-year outcomes in the phase III CROWN trial showed that median progression-free survival had not been reached in previously untreated patients receiving lorlatinib vs a median of 9.1...

pancreatic cancer

Previously Untreated Metastatic Pancreatic Cancer: CD40 Agonist Plus mFOLFIRINOX

In a European phase Ib/II study (OPTIMIZE-1) reported in The Lancet Oncology, Jean-Luc Van Laethem, MD, and colleagues found that the combination of the CD40 agonist antibody mitazalimab with mFOLFIRINOX (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan) showed activity in previously...

supportive care

Carboplatin-Induced Nausea and Vomiting: Addition of Olanzapine to Triple Antiemetic Therapy

In a Japanese phase III trial reported in the Journal of Clinical Oncology, Inui et al found that the addition of olanzapine to triple antiemetic therapy did not improve the prevention of carboplatin-induced vomiting in patients with thoracic cancers who had received no prior chemotherapy; however, ...

Advertisement

Advertisement




Advertisement